VYNE Therapeutics Inc. (NASDAQ:VYNE) Stock Gains Momentum: Jumps 10% in a Month
VYNE Therapeutics Inc. (NASDAQ:VYNE) up 10% in a month. Recently the company established a Scientific Advisory Board comprising leading clinicians and scientists that specialize in inflammatory and immunological diseases.
Market Stats
On Friday, VYNE stock fell 0.72% at $1.37 with more than 442k shares, compared to its average volume of 898K shares. The stock has moved within a range of $1.3500 – 1.4200 after opening the trade at $1.40.
Formation of Scientific Advisory Board
The advisory board will offer guidance and scientific expertise to the company’s management and Board as VYNE advances its innovative immune-inflammatory treatments pipeline.The innovative treatments include the proprietary bromodomain and extra-terminal inhibitor compounds that are licensed through the company’s partnership with In4Derm Limited and FMX114 for possible mild-to-moderate atopic dermatitis treatment.
CEO David Domzalski said that the company recently announced a new strategic direction focusing on progressing its novel pipeline and development of treatments for inflammatory and immunological diseases. The formation of the SAB is a significant step in the company’s development plans. Domzalski added that they are pleased to welcome the team of scientists and clinicians to the company to help advance VYNE’s objectives and drug development efforts. So, investors should keep an eye on VYNE in the coming months.
Key Quote
“We recently announced our new strategic direction to focus on advancing our proprietary pipeline and develop treatments for immunological and inflammatory diseases,” said David Domzalski, CEO of VYNE. “The establishment of the SAB is an important step in our development plans, and we are delighted to welcome this team of esteemed and world-renowned medical experts who bring significant expertise, highly complementary skills and an external perspective.”
Traders Corner
VYNE stock is trading below the 200-Day and 50-Day Moving averages of $4.22 and $1.41 respectively. However, the stock is trading above 20-Day moving average of $1.32. The stock is up 15% in the past month.